$-0.56 EPS Expected for Tocagen Inc. (TOCA)

July 13, 2018 - By Andrea Pope

Analysts expect Tocagen Inc. (NASDAQ:TOCA) to report $-0.56 EPS on August, 8.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.56 EPS. After having $-0.65 EPS previously, Tocagen Inc.’s analysts see -13.85 % EPS growth. The stock decreased 0.31% or $0.03 during the last trading session, reaching $9.53. About 67,403 shares traded. Tocagen Inc. (NASDAQ:TOCA) has declined 44.41% since July 14, 2017 and is downtrending. It has underperformed by 56.98% the S&P500.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. The company has market cap of $189.77 million. The Company’s cancer-selective gene therapy platform is built on retroviral replicating vectors , which are designed to deliver therapeutic genes into the DNA of cancer cells. It currently has negative earnings. The company??s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG).

More recent Tocagen Inc. (NASDAQ:TOCA) news were published by: Streetinsider.com which released: “UPDATE: Ladenburg Thalmann Starts Tocagen Inc. (TOCA) at Buy” on June 27, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018. Benzinga.com‘s news article titled: “26 Stocks Moving In Tuesday’s Pre-Market Session” with publication date: June 26, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.